
|Videos|March 15, 2021
Dr. Tward discusses his experience with the Prolaris test for prostate cancer
Author(s)Urology Times staff
“It’s an extremely useful tool,” says Jonathan D. Tward, MD, PhD, of the Prolaris test.
Advertisement
“I think that getting a really personalized risk estimator can give you a better handle on how much you need to do to achieve the best outcome,” says Jonathan D. Tward, MD, PhD, in discussing the Prolaris test and how his use of the test has evolved over time. Tward is a professor of radiation oncology at the University of Utah, Salt Lake City.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












